Chloroquine Inhibits the Release of Inflammatory Cytokines by Human Lung Explants

被引：9

作者：

Grassin-Delyle, Stanislas ^{[1
,2
]}

Salvator, Helene ^{[1
,3
]}

Brollo, Marion ^{[3
]}

Catherinot, Emilie ^{[1
]}

Sage, Edouard ^{[1
,4
]}

Couderc, Louis-Jean ^{[1
,3
]}

Naline, Emmanuel ^{[1
,3
]}

Devillier, Philippe ^{[1
,3
]}

机构：

[1] Foch Hosp, Dept Resp Dis, Suresnes, France

[2] Univ Paris Saclay, Dept Biotechnol Sante, INSERM Infect & Inflammat, Montigny Le Bretonneux, France

[3] Univ Paris Saclay, Foch Hosp, Lab Res Resp Pharmacol, Exhal Facil, Suresnes, France

[4] Univ Paris Saclay, INRAE, UMR0892, Jouy En Josas, France

来源：

CLINICAL INFECTIOUS DISEASES | 2020年 / 71卷 / 16期

关键词：

chloroquine; lung explant; tumor necrosis factor-alpha; interleukin-6; chemokine; COVID-19; STORM;

D O I：

10.1093/cid/ciaa546

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

On human lung parenchymal explants, chloroquine concentration clinically achievable in the lung (100 mu M) inhibited the lipopolysaccharide-induced release of TNF-alpha (by 76%), IL-6 (by 68%), CCL2 (by 72%), and CCL3 (by 67%). Besides its antiviral activity, chloroquine might also mitigate the cytokine storm associated with severe pneumonia caused by coronaviruses.

引用

页码：2265 / 2268

页数：4

共 15 条

[1] Roflumilast Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor-α and Chemokine Production by Human Lung Parenchyma [J].

Buenestado, Amparo ;

Chaumais, Marie-Camille ;

Grassin-Delyle, Stanislas ;

Risse, Paul-Andre ;

Naline, Emmanuel ;

Longchampt, Elisabeth ;

Tenor, Hermann ;

Devillier, Philippe .

PLOS ONE, 2013, 8 (09)

[2]

Cao R, 2020, CELL RES, V30, P269, DOI [DOI 10.1038/S41422-020-0282-0, 10.1038/s41422-020-0282-02020, DOI 10.1038/s41422-020-0282-0]

[3] Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology [J].

Channappanavar, Rudragouda ;

Perlman, Stanley .

SEMINARS IN IMMUNOPATHOLOGY, 2017, 39 (05) :529-539

[4] New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? [J].

Devaux, Christian A. ;

Rolain, Jean-Marc ;

Colson, Philippe ;

Raoult, Didier .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (05)

[5] Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [J].

Gao, Jianjun ;

Tian, Zhenxue ;

Yang, Xu .

BIOSCIENCE TRENDS, 2020, 14 (01) :72-73

[6] Bitter Taste Receptors (TAS2Rs) in Human Lung Macrophages: Receptor Expression and Inhibitory Effects of TAS2R Agonists [J].

Grassin-Delyle, Stanislas ;

Salvator, Helene ;

Mantov, Nikola ;

Abrial, Charlotte ;

Brollo, Marion ;

Faisy, Christophe ;

Naline, Emmanuel ;

Couderc, Louis-Jean ;

Devillier, Philippe .

FRONTIERS IN PHYSIOLOGY, 2019, 10

[7]

Guadagno L., 2020, LANCET, V60, DOI DOI 10.1016/S0140-6736(20)30183-5

[8] TISSUE DISTRIBUTION OF CHLOROQUINE HYDROXYCHLOROQUINE AND DESETHYLCHLOROQUINE IN RAT [J].

MCCHESNEY, EW ;

BANKS, WF ;

FABIAN, RJ .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 1967, 10 (03) :501-+

[9] COVID-19: consider cytokine storm syndromes and immunosuppression [J].

Mehta, Puja ;

McAuley, Daniel F. ;

Brown, Michael ;

Sanchez, Emilie ;

Tattersall, Rachel S. ;

Manson, Jessica J. .

LANCET, 2020, 395 (10229) :1033-1034

[10]

Mzayek Fawaz, 2007, PLoS Clin Trials, V2, pe6, DOI 10.1371/journal.pctr.0020006

← 1 2 →